美股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 来源：环球市场播报 信达生物发布公告，关公司于2026年2月8日就与礼来制药签署战略合作协议以推动肿瘤学及免疫学领域 新药研发所作出的公告。公司已获联邦贸易委员会提前批准，至此，礼来制药与公司之间战略合作协议 生效的所有先决条件均已达成。该战略合作协议已于香港时间2026年3月24日生效。 公司注意到，部分媒体报导错误地将该战略合作协议的生效解读为对公司的收购。公司谨此澄清，公司 并未，亦无意进行该等交易。谨此提醒股东及有意投资者，切勿依赖有关集团的市场传闻。有关集团的 任何资讯，应仅以公司的官方公告为准。 ...

Like many growth stocks, drugmaker Eli Lilly (NYSE: LLY) is down sharply year to date. Its 15.6% decline is weighing on the healthcare sector, as research by The Motley Fool shows that Lilly is by far the most valuable U.S. healthcare company. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Below we'll look at why it's under pressure, a ...

Quick Read iShares U.S. Pharmaceuticals ETF (IHE) has 46.8% of its $1.1B portfolio concentrated in Johnson & Johnson (JNJ), up 14% year-to-date on strong DARZALEX sales of $3.90B, and Eli Lilly (LLY), down 15% year-to-date despite Mounjaro hitting $7.41B in Q4 2025 revenue. The fund itself is flat year-to-date, down 0.5%, reflecting opposing performance between its two dominant holdings facing pricing pressure and manufacturing constraints. The Trump administration’s aggressive drug pricing reform thro ...

Eli Lilly & Company (NYSE:LLY) ranks among the best high profit margin stocks to buy. Following the reveal of an innovative employer access platform for obesity therapies, Morgan Stanley reiterated its Overweight rating and $1,313 price target for Eli Lilly & Company (NYSE:LLY) on March 5. Eli Lilly recently established its Employer Connect platform in the US, which provides flexible benefit designs geared at increasing access to obesity treatments like Zepbound. Pixabay/Public Domain In order to produc ...

2026.03. 24 本文字数：2990，阅读时长大约5分钟 作者 | 第一财经 吴斯旻 "十五五"规划纲要明确提出实施健康优先发展战略，并将生物制药列为新兴支柱产业，为跨国医药企 业参与"健康中国"建设提供了新机遇。 近日，"中国发展高层论坛2026年年会"（下称"年会"）召开。年会期间，国家卫健委和中央财经委等 有关部门均释放了深化医药卫生体制改革、促进医疗等重点领域科技创新、优化营商环境和加大对外 开放的积极信号。 多名与会跨国医药企业高管均积极回应，将扩大在华业务，加大在细胞疗法等前沿领域的本地化生产 能力，继续投资本地创新并加强创新合作。 在深度参与中国医药创新的过程中，这些跨国医药企业对中国医药创新生态也有更多期待：其一，优 化完善与创新相匹配的知识产权保护体系、价值认定和支付机制，为企业提供制度性激励；其二，以 临床需求为导向，推动市场和监管的关注点从产品创新转向系统性集成创新，加大中国在疾病治理和 创新方案上的输出能力，完善涵盖患者、医疗机构、国内外制药企业和科研院所、社会资本以及监管 部门等多方的医药创新生态。 跨国药企深化在华布局 据国家卫健委消息，22日，上述年会"谋划'十五五'国民健 ...

More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions. The discussions reflected a cautious but clear pivot toward expansion, as Beijing continues to gradually ease restrictions on foreign businesses.Eli Lilly Expands China Bet With Obesity Drug FocusIn March, Eli Lilly outlined an aggressive long-term strategy for China, announcing plans to invest $3 billion in the country over the ...

Core Viewpoint - Eli Lilly has experienced significant stock growth, with a 400% increase over the past five years, but its high valuation raises questions about future investment potential [2]. Group 1: Stock Performance and Valuation - Eli Lilly's current market cap exceeds $800 billion, and it trades at approximately 40 times its trailing earnings [2]. - The consensus analyst price target for Eli Lilly is slightly over $1,221, indicating a potential upside of about 35% from its current price [6]. - Despite a 16% decline in stock value this year, Eli Lilly has been underperforming compared to the S&P 500 [9]. Group 2: Earnings and Growth Potential - In the fourth quarter of 2025, Eli Lilly reported a 43% increase in sales to $19.3 billion and a 50% rise in net income to $6.6 billion, driven by its popular GLP-1 drugs, Mounjaro and Zepbound [7]. - Analysts maintain a bullish outlook, with 25 out of the last 30 ratings being buy ratings, reflecting strong growth expectations [6][8]. - Long-term investors may see even stronger returns if Eli Lilly continues to lead in the GLP-1 market [8].

在阿斯利康宣布计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品 生产与研发领域的布局后， 多家跨国药企（MNC）接连宣布加大中国市场投资。 近日，中国发展高层论坛2026年年会现场涌动着一股"MNC投资热度"。诺华公司首席执 行官万思瀚（Vasant Narasimhan）在"健康中国2030"与大健康产业发展专题研讨会上宣 布，诺华计划在华投入超过33亿元人民币启动大规模投资扩建。而在同一周，阿斯利康刚 刚宣布在上海和广州落子两大重磅生产基地，礼来则抛出了未来十年累计投资30亿美元的 计划。 记者丨季媛媛 编辑丨张明艳 跨国药企投资中国成为当下的一大热点。 在中国发展高层论坛2026年年会召开前夕，阿斯利康宣布在上海建设细胞疗法生产供应基地 与创新中心，打造端到端的细胞治疗能力；几乎同时，其在广州的放射性偶联药物生产供应 基地也浮出水面。这两大基地的协同，将显著增强阿斯利康在新型药物及疗法领域的本地化 生产能力。 阿斯利康全球执行副总裁、国际业务负责人尹思睿（Iskra Reic）表示："三十余年来，我们始 终与中国携手合作，为患者带来科学突破成果。依托今年1月宣布的逾1000 ...

2026.03. 23 本文字数：1454，阅读时长大约2分钟 刚刚过去的这一周，阿斯利康接连宣布要在华建立两个基地，一是在上海建立细胞疗法商业化生产供 应基地与创新中心；二是在广州建设放射性偶联药物生产供应基地。 作者 | 第一财经 林志吟 3月22日，诺华公司宣布将持续加大在华投资，扩大在中国研发、生产及运营布局，预计将投入金额 超过33亿元。 从诺华公司发布的消息看，这项大规模的投资计划将在今年启动。 诺华方面介绍称，诺华昌平工厂始建于1987年，具备年产30亿片（粒）制剂及5.5亿盒包装的最大产 能，是诺华全球制造供应网络中的重要生产基地。当前，工厂已启动新一轮厂区扩建升级项目，并规 划未来持续投入约15亿元，用于建设新厂房及配套设施，引入无菌制备工艺、液体灌装及包装等全 新生产技术和设备。 此外，诺华中国总部所在地——上海园区将在今年迎来投入运营十周年的里程碑。诺华已计划联合投 资人共同出资18亿元人民币，启动上海园区二期项目建设。 今年以来，密集有跨国药企宣布在华启动大规模投资计划。 同样在3月份，礼来宣布，计划未来十年累计投资30亿美元全面扩展在华供应链产能，打造口服固体 制剂本土生产与供应体系 ...

Core Insights - Eli Lilly and Company is recognized as a strong investment opportunity, particularly with the launch of its weight-loss drug Zepbound, which will be available for self-pay at $299 per month for the 2.5 mg dose [1] Group 1: Product Launch and Pricing - Zepbound, a once-weekly injectable for adults with obesity or overweight-related conditions, will be available for self-pay starting at $299 per month [1][2] - A new savings card will allow eligible adults with a valid prescription to access the same pricing nationwide, although it is limited to the KwikPen format [2] Group 2: Access and Cost Reduction Initiatives - Eli Lilly received a boost from new Medicare and Medicaid services implementation details aimed at enhancing access to medications at lower costs [3] - With the new Medicare and Medicaid Services details, Zepbound and other medications will be available through Medicare Part D plans, capping out-of-pocket costs for beneficiaries at $50 a month, with cost-sharing limited to $245 a month before reaching the deductible [4] Group 3: Company Overview - Eli Lilly is a global pharmaceutical leader focused on developing medicines for diabetes, obesity, cancer, and immunological disorders, with notable products including Mounjaro and Zepbound [5]